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Abstract. Myosmine (3-(1-pyrrolin-2-yl)pyridine) is an alkaloid found in tobacco as well as various staple 
foods, fruits and vegetables. Myosmine has recently been suspected to be a tobacco-independent carcino-
genic source. Using cell flow cytometry, we have examined the influence of myosmine on the cell cycle 
of murine erythroleukemia (MEL) cells in vitro and have compared this with its effects on murine bone 
marrow cells in vivo. Myosmine at low concentrations inhibited cell proliferation dose dependently; while 
at concentrations close to 300 µmol dm−3 it acted in a cytostatic fashion, that is, it increased the percen-
tage of cells in the S and G2/M phases. At doses of 350–400 µmol dm−3 myosmine induced apoptosis and 
the hypoploid fraction. In vivo intraperitoneal injection of mice with 100 mg/kg of myosmine resulted in a 
statistically significant increase in the percentage of cells in S phase; i.e. from 13.75 to 18.22 %. The per-
centage of bone marrow cells in the G2/M phase increased from 6.79 to 8.93 % in treated mice compared 
to controls. All of these results are in agreement with the hypothesis that myosmine possesses genotoxic 
potential. (doi: 10.5562/cca1767) 
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INTRODUCTION 
Myosmine, 3-(1-pyrrolin-2-yl)pyridine, as well as nico-
tine, is among the fully structurally characterized tobac-
co alkaloids.1 Unlike nicotine, myosmine is found in 
various commonly consumed foods such as nuts, vege-
tables, and fruits.2,3 It is not surprising therefore, that 
myosmine has also been detected in human toenail, 
plasma and saliva from normal controls.4 After nitrosa-
tion and/or peroxidation, myosmine gives rise to reac-
tive pyridyloxobutylating species which are capable of 
forming pyridyloxobutylated DNA adducts.5–8 Nitrosa-
tion of myosmine also leads to the formation of the 
esophageal carcinogen N '-nitrosonornicotine.5 Original-
ly, nitrosonornicotine and 4-hydroxy-1-(3-pyridyl)-1-
butanone (HPB)-releasing adducts were thought to be 
highly tobacco-specific. 
A number of scientists connect human intake of 
myosmine to the increase in incidence of esophageal 
adenocarcinoma in the Western world.9 In support of 
this hypothesis, there is data which shows that in sudden 
death victims HPB-releasing DNA adducts found in 
esophageal mucosa taken from close to the esophagoga-
stric junction, were similar in quantity in smokers and 
nonsmokers.10 It was therefore hypothesized that a to-
bacco-independent source for these adducts might have 
been myosmine uptake from food.2,3,5,6 
The genotoxicity of myosmine has been studied in 
a number of in vitro models. Comet assay studies have 
shown that myosmine induces DNA damage in nasal 
mucosa cells, human lymphocytes and in cell lines de-
rived from human esophageal adenocarcinoma.11,12 In 
another investigation, the mutagenic potential of myos-
mine was demonstrated in human lymphocytes using 
the human lymphocyte hypoxanthine guanine phospho-
ribosyl transferase gene mutation assay.13 
It has been shown that eukaryotic cells respond to 
DNA damage by inducing temporary cell cycle arrest at 
the G1/S and G2/M transition points;14 these transient 
delays in cell cycle progression presumably allow time 
for repair and prevent the replication and segregation of 
damaged DNA templates. That is why it is interesting to 
investigate whether or not myosmine is also able to 
influence the cell cycle both in vitro and in vivo. As our 
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in vivo model we have chosen to study bone marrow 
cells because the generally accepted method for deter-
mining the carcinogenic potential of a substance is the 
mouse micronucleus assay,15 an assay which uses bone 
marrow polychromatic erythrocytes. In order to correct-
ly interpret our in vivo results, it was logical to study the 
effect of myosmine in the closest possible in vitro mod-
el, and for this we chose Friend murine erythroleukemia 
cells, virally transformed erythroid precursors that are 
held in an immature and proliferating state.16 The meta-
bolism of these cells is similar to that of the majority of 
proliferating hematopoietic cells in the bone marrow.17 
 
MATERIALS AND METHODS 
Materials 
Myosmine was synthesized in the Institute of Molecular 
Biology, Bulgarian Academy Science (BAS), in accor-
dance with the published method of Brandänge and 
Lindblom (1976).18 The product was found to be 99.9 % 
pure; it’s identity with commercial myosmine was con-
firmed by ultraviolet and infrared spectral analysis, gas 
chromatography and high pressure liquid chromatogra-
phy. All other reagents were purchased from Sigma-
Aldrich Chemie GmbH, Deisenhofen, Germany and 
were of analytical grade. The solutions needed for flow 
cytometric analysis were obtained from BD Bioscience. 
 
Cell Culture 
Murine erythroleukemia cells, clone F4N (virus-
transformed erythroid precursor cells)16 were cultured in 
Dulbecco's modified Eagle medium (Gibco) supple-
mented with 10 % calf serum, and cultured in a 5 % 
CO2 atmosphere at 37 C, and passed every day at a 
concentration of 5×105 cells/ml. 
 
Incubation with Myosmine and In Vitro  
Cytotoxicity Test 
An aliquot of 5×105 cells/ml in the exponential phase of 
growth was incubated with myosmine in 24-well micro-
titer plates. After 24 or 48 hours of treatment with 
myosmine, the cells were counted hemocytometrically 
and prepared for cell cycle analysis. The number of 
dead cells was determined by staining with trypan blue. 
The mean ± SD of triplicate determinations of viable 
cells was calculated. The fraction of cells undergoing 
apoptosis was determined using fluorescent microscopy 
with propidium iodide. 
 
Animals 
30–40 day-old BALB/c mice weighing 25–30 g were 
obtained from the National Center of Public Health 
Protection. They received proper care and were pro-
vided with food and water ad libitum. Each group of 6 
mice was treated with an intraperitoneal injection of 
various concentrations of myosmine diluted in sterile 
water and housed in a separate compartment. Experi-
ments were performed in accordance with the guidelines 
for Care and Use of Laboratory Animals under work 
permit №11130007 of the Institute of Molecular Biolo-
gy, Bulgarian Academy of Sciences. 
 
Bone Marrow 
Twenty four hours after their last treatment with myos-
mine, mice were killed by cervical dislocation. The left 
femur was removed and the bone marrow cavity was 
flushed with 1 ml Hanks Balanced salt solution (HBSS). 
The extracted bone marrow was suspended in cold 
HBSS, and the cells were suspended in the solution by 
passing them through a 70 μm nylon mesh (Cell Strain-
er, BD Falcon). Five mls of 70 % ethanol was added 
dropwise to the cells while vortexing. Cells were stored 
at −20 oC for 24 hours to fix. 
 
Cell Cycle Analysis 
After 24 h incubation with different concentrations of 
myosmine, the cells were harvested by centrifugation 
and resuspended in 0.5 ml cold PBS. A quantity of 70 % 
ethanol was added dropwise to the cells while vortex-
ing. Cells were stored at −20 oC 24 hours to fix. Just 
before flow cytometric analysis (FACS) cells were spun 
down, washed with PBS and resuspended in propidium 
iodide (PI) staining solution containing 100 μg/ml 
RNase and 50 μg/ml PI. FACS analysis was performed 
on a FACSCalibur (Beckton Dikinson) using the FL3-A 
channel. A minimum of 10 000 cells were analyzed 
from each cell sample and the resulting histograms were 
evaluated using WinMDI 2.9 software. 
 
Statistical Analysis 
The percentage of bone marrow cells in each phase of 
the cell cycle was expressed as the mean ± SD. Differ-
ences between control and treated samples were ana-
lyzed for significance by Student’s t test. A P value of 
<0.05 indicated statistical significance. 
 
RESULTS AND DISCUSSION 
In Vitro Cytotoxicity of Myosmine 
For this study we used mouse erythroleukemia cells, 
clone F4N, in which several antitumor drugs have al-
ready been shown to readily trigger apoptosis.19,20 The 
growth inhibitory and cytotoxic effect of incubation of 
MEL cells with different concentrations of myosmine 
have been shown in Figure 1. The presence in the cell 
culture of concentrations of myosmine lower than  
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50 μmol dm−3 did not influence cell proliferaton, where- 
as higher concentrations of myosmine were found to 
inhibit cell growth. Twenty four hours after incubation 
with either 300 and 400 μmol dm−3 myosmine a 
cytostatic effect was observed, and by 48 hours post 
treatment all cells were dead. This time course suggests 
programmed cell death rather than necrosis. To further 
clarify the mode of cell death, samples were examined 
by fluoroscent microscopy. Using this method as well as 
the comet assay, we have previously shown20 that apop-
totic MEL cells exhibited changed morphology with 
fragmented condensed nuclei, while untreated control 
cells displayed uniform size and morphology. Myos-
mine, when added to cells in cytotoxic concentrations, 
induced apoptosis, and cells showed typical fragmented 
condensed nuclei, ghosts, and apoptotic bodies. 
At concentrations of myosmine higher than 500 
μmol dm−3 all cells appeared dead by 24 hours; some 
with typical apoptotic morphology, while others 
appeared necrotic. All of the cells were trypan blue 
positive, reflecting the fact that all had a defective 
external cell membrane. We have not presented photos 
of the apoptotic cells in this publication as they will 
published in a future article devoted to pro and anti 
apoptogenic action of myosmine. 
 
In Vitro Effect of Myosmine on Cell Cycle 
Progression 
To further analyze the nature of cell death, flow cytome-
tric analysis was performed. If myosmine forms DNA 
adducts and the damage is significant enough, the cell 
cycle with be temporarily arrested, allowing the cells 
time for repair. In this study, MEL cells were incubated 
for 48 hours with different doses of myosmine (Figure 
2). At a concentration of 100 μmol dm−3 myosmine 
there was a decrease in the cell fraction in the G1/0 
phase from 44 to 29 % and an increase in G2/M from 20 
to 29 %. After treatment with 150 μmol dm−3 myos-
mine, the fraction of cells in G2/M had increased signif-
icantly to 36 %. At 200 μmol dm−3 myosmine the most 
characteristic change was a dramatic increase in the 
Figure 1. The dependence of the number of viable murine
leukemia cells on myosmine concentration. Cells were treated
with different concentrations of myosmine for 24 or 48 hours.
 
Figure 2. The influence of myosmine on cell cycle kinetics of 
murine leukemia cells. Cells were treated with different con-
centrations of myosmine for 48 hours. The histograms are 
from one typical experiment. 
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fraction of hypoploid cells to 33 % compared to 2 % in 
the control cells. According to the morphological analy-
sis these were apoptotic cells. At 300 μmol dm−3 there 
was an additional increase in the fraction of cells in 
G2/M and a decrease in the number of hypoploid cells, 
probably a result of increased toxicity of higher concen-
trations of myosmine. 
These results demonstrate that MEL cells responds 
to myosmine in the same way as they do to other geno-
toxic stressors, that is, by activating cell cycle check-
points and by altering progression to the G2/M stage of 
the cell cycle, thus allowing the cells time to repair 
damage or move into apoptosis. 
 
In Vivo Effect of Myosmine on the Cell Cycle 
Former studies have shown that the LD50 for myosmine 
in rats is 190 mg/kg (i.p.) and 1875 mg/kg (p.o.).21 
There is no available data on the acute toxicity of 
myosmine in mice. Therefore our first task was to find 
out the maximal tolerable dose of myosmine when giv-
en intraperitoneally to mice. Balb/C mice of 25–30 g 
were divided into groups of 2 animals and injected with 
myosmine in doses of 60, 125, 250, 500 mg/kg. Mice 
injected with either 500 or 250 mg/kg died within two 
minutes. When two mice were given 125 mg/kg, one 
lived and the other died. At 60 mg/kg, both animals 
lived. An additional two animals were then injected 
with 100 mg/kg, and both lived. Therefore we con-
cluded that the maximum tolerable dose was approx-
imately 100 mg/kg. This does was then used in the in 
vivo experiments. 
The cell cycle distribution in bone marrow was 
studied 24 h after a single injection of 100 mg/kg 
myosmine (Table 1). Control mice were injected with a 
similar quantity of sterile water. There was a statistical-
ly significant increase in the percentage of cells in S 
phase (i.e. from 13.75 to 18.22 %) and in the G2/M 
phase from 6.79 to 8.93 % in the bone marrow isolated 
from treated mice compared to that of controls. It is 
likely that the in vivo effects were much less pro-
nounced than the in vitro because only a portion of the 
bone marrow cells would have been in a proliferating 
state, while the remainder of the cells would have been 
in the G0/G1 phase. There are no studies providing 
evidence for the accumulation of myosmine or myos-
mine’s carcinogenic intermediates in bone marrow. In 
this study we have therefore acquired additional confir-
mation that myosmine or its metabolites reaches the 
bone marrow and influences cell division. 
 
CONCLUSION 
Our investigation has shown the ability of myosmine 
to inhibit cell proliferation and to alter cell cycle kinet-
ics. The mode of cytotoxic action depends on the con-
centration of myosmine: at low concentrations it inhi-
bited cell proliferation dose dependently; at concentra-
tions close to 300 µmol dm−3 myosmine acts in a cy-
tostatic fashion, that is, increasing the percentage of 
cells in the S and G2/M phases. At 350–400 µmol 
dm−3, myosmine induces apoptosis and the hypoploid 
fraction. In vivo treatment of mice with myosmine 
resulted in an increased percentage of bone marrow 
cells in S and G2/M phases, the same effect as was 
found in vitro. All of these results are in agreement with 
the hypothesis that myosmine possesses genotoxic poten-
tial. 
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